The International Journal of Tuberculosis and Lung Disease 21(5) DOI: 10.5588/ijtld.16.0518
front cover © Hannah Maule-Ffinch/Save the Children
This report of the EFSA and ECDC presents the results of zoonoses monitoring activities carried out in 2020 in 27 EU Member States (MS) and nine non-MS. Key statistics on zoonoses and zoonotic agents in humans, food, animals and feed are provided and interpreted historically.
Mental illness can affect not only the life of the person with the illness, but also their close family, partners
and friends. Significant people in a person’s life are often a source of support with the illness.
However, family, partners and friends may be faced with a loved one’s men...tal illness without much
information on ways to deal with it and its impact on their life.
NOTE: This guide is NOT a replacement for medical advice and we strongly recommend that you or the person you care
for discuss issues related to treatment with a clinician.
more
This handbook reflects and updates the work that ECLAC has done in recent decades to establish a methodology for estimating the economic consequences of a disaster, and thus determine the financing required to rebuild and return the affected area to normal. The handbook's third edition strengthens p...rocedures for estimating the effects of disasters, for distinguishing between losses and additional costs and systematizing the links that exist between different sectors of the economy
more
The Lay Counselor Cadre in Botswana
Le document fournit des directives complètes pour la gestion des épidémies de choléra, y compris la prévention, le diagnostic et le traitement. Il met l'accent sur les mesures de réponse rapide, l'importance de la thérapie de réhydratation (orale et intraveineuse), ainsi que sur les interven...tions de santé publique telles que l'assainissement de l'eau, la promotion de l'hygiène et la surveillance épidémiologique pour contrôler la propagation du choléra dans les communautés affectées. Ce matériel est conçu comme une ressource pour les professionnels de santé et les autorités de santé publique.
more
Step-by-step risk management guidance for drinking-water supplies in small communities.
Q12. SCOPING QUESTION: In people with psychotic disorders, including schizophrenia and bipolar disorder, are recovery-oriented strategies enhancing vocational and economic inclusion (such as supported employment) feasible and effective?
Over the reporting period, THP-Burkina Faso (THP-Burkina) maintained a continuous focus on ensuring the selfreliance of the health program in each of its epicenters. Building upon its exclusive use of government-run health clinics at its epicenters, THP-Burkina developed a firstever partnership agre...ement with the national Ministry of Health. This allowed greater partnership with medical professionals at the epicenter level, as was practiced at Boulkon Epicenter in June 2012 (see photo). THPBurkina continued advancing four of its 10 Phase III epicenter rural banks toward government recognition.
more
Q6: In individuals with psychotic disorders (including schizophrenia) who require long term antipsychotic treatment, are anticholinergic medications more effective in preventing or reducing extrapyramidal side-effects and/or improving treatment adherence than placebo/treatment as usual?
Euro Surveill. 2016;21(12):pii=30174. DOI: http://dx.doi.org/10.2807/1560-7917.ES.2016.21.12.30174
Offical Statement
INT J TUBERC LUNG DIS 12(12):1376–1379
Monitoring is a crucial element in any successful programme. It is important to
know if health care facilities – and ultimately countries – are meeting the agreed
goals and objectives for preventing and managing cardiovascular diseases (CVD).
Monitoring is the on-going collection, management ...and use of information to
assess whether an activity or programme is proceeding according to plan and/
or achieving defined targets. Not all outcomes of interest can be monitored. Clear
outcomes must be identified that relate to the most important changes expected to result from the project and to what is realistic and measurable within the timescale of the project. Once these outcomes have been articulated, indicators can be chosen that best measure whether the desired outcomes are being met.
To allow progress to be monitored, this module provides a set of indicators on
CVD management. Agreeing on a set of indicators allows countries to compare
progress in CVD management and treatment across different districts or
subnational jurisdictions, as well as at a facility level, identify where performance
can be improved, and track trends in implementation over time. Monitoring
these indicators also helps identify problems that may be encountered so that
implementation efforts can be redirected.
This module starts from the collection of data at facility level, which is then
“transferred up” the system: facility-level data are aggregated at subnational level
to produce reports that allow tracking of facility and subnational performance over time and allow for comparison among facilities. National-level data are obtained through population-based surveys.
Implementing a monitoring system requires action at many levels. At national and
subnational levels, staff can determine how best to integrate data elements into
existing data collection systems – such as the routine service-delivery data that are collected through facility-level Health Management Information Systems (HMIS).
In the facility setting, personnel must be aware of what data are needed. Sample
data-collection tools are included, recognizing that countries use different datamanagement systems for HMIS, so the CVD monitoring tools will be adapted to work with the HMIS system being used by the country, such that the indicators can be collected with minimal disruption/work to existing systems and tools
more
Globally each year, millions of people suffer illness or lose their lives because the vaccines, medicines and diagnostic tests that they need are either unavailable or unaffordable – and this lack of access to medicine is acute in low- and middle-in-
come countries (LMICs). While the COVID-19 pan...demic laid this inequity bare, it also saw the pharmaceutical industry develop and bring new vaccines and treat- ments to market at unprecedented speed. As the world emerges from the worst
of this crisis, pharmaceutical companies are now at an important juncture, where lessons learned from the pandemic can prove pivotal in finding solutions to bridge long-standing gaps in access to medicine in LMICs.
more